Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis

Abstract

Introduction

Influenza is an important cause of morbidity and mortality in Europe. Prevention by annual vaccination is most effective but with yearly vaccine reformulation to match circulating virus strains, vaccine safety must be continuously monitored. The European Medicines Agency published guidance on safety monitoring of influenza vaccines.

Methods

An enhanced safety surveillance study of GSK’s inactivated quadrivalent influenza vaccine (IIV4) was conducted in Belgium, Germany, and Spain in influenza season 2018/19. The objective was to collect adverse event (AE) reports from subjects within 7 days of vaccination. A customized AE reporting card (AERC) with predefined AEs of interest was used to rapidly detect and evaluate potential new safety concerns. Interim results are presented here.

Results

Between week 40 and 52, 1060 vaccinated subjects were enrolled (31.0% Belgium, 26.2% Germany, and 42.7% Spain) covering all ages for which IIV4 is indicated (32.0% aged 6 months–17 years, 33.8% 18–65 years, and 34.2% over 65 years). Pediatric subjects  less than 9 years old (n = 139) received two doses. Following dose 1 and dose 2, 98.2% and 100%, respectively, returned the completed AERC recording any AEs. Following dose 1 and dose 2, 454 and 34 subjects, respectively, reported at least one AE (most frequently expected general and injection site symptoms and respiratory symptoms).

Conclusion

All reported AEs were expected as per summary product characteristics (smPC). No safety signals that impact public health or alter the benefit–risk profile of GSK’s IIV4 were identified. Subjects from all vaccinated age groups were enrolled and the use of AERCs allowed rapid monitoring and analysis of reported AEs.

Trial Registration

ClinicalTrials.gov identifier, NCT03688620.

Funding

GlaxoSmithKline Biologicals SA.

Electronic supplementary material

The online version of this article (10.1007/s12325-019-01105-2) contains supplementary material, which is available to authorized users.

Introduction

The burden of seasonal influenza in Europe is substantial. A study published by the European Center for Disease Prevention and Control (ECDC) in 2018 ranked influenza as having the highest burden among 31 infectious diseases assessed. Influenza incidence and mortality were high with 5887 cases and 5.89 deaths per 100,000 population. Compared to the other infectious diseases, the burden of influenza ranked second for the age group under 15 years, third among adults (16–64 years), and was by far the highest among older people (over 65 years) [1].

Seasonal epidemics of influenza are caused by circulating influenza A virus subtypes and B virus lineages. Annual vaccination is the most effective approach to preventing influenza and its complications [2]. The influenza virus, however, undergoes frequent genetic and antigenic changes; therefore, each year new vaccines are formulated to match the circulating virus strains, based on recommendations from the World Health Organization (WHO) [3].

GSK’s seasonal inactivated quadrivalent influenza vaccine (IIV4) is indicated for active immunization of adults and children from 6 months of age for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus lineages contained in the vaccine.

As seasonal vaccines are typically reformulated annually and introduced in a short time span and to a large number of people, their benefit–risk profile must be routinely monitored and their safety rapidly assessed [4]. The European Medicines Agency (EMA) updated their guidance to vaccine manufacturers in this respect in 2014, no longer recommending small clinical trials for newly formulated vaccines prior to introduction, as these provided limited information on expected efficacy and safety [5]. Instead, they recommend early annual enhanced safety surveillance in one or several European Union member states, where data and systems permit the objective to be met quickly. The main objective is to rapidly detect and act on any new safety signals, i.e., increased frequency or severity of expected reactogenicity (e.g., local, systemic, or allergic events) intrinsic to each vaccine, compared to previous season or clinical trial rates, that could indicate a more serious risk [4].

Following an initial pilot study in the United Kingdom (UK) [6] in influenza season 2015/16, GSK refined an enhanced safety surveillance (ESS) methodology, using customized adverse event reporting cards (AERC). This was then successfully applied in the UK to assess vaccine safety in influenza seasons 2016/17 [7, 8] and 2017/18 (NCT03278067), mostly in adults and older adults because of preferential local recommendations for a live attenuated influenza vaccine (LAIV), except when contraindicated. In both studies, using the AERC increased reporting of EMA-specified adverse events of interest (AEIs) compared with electronic health records which require a medical visit.

The objective of the current ESS study for influenza season 2018/19 was to collect safety data for GSK’s IIV4 in Belgium (AlphaRix Tetra), Germany (Influsplit Tetra), and Spain (Fluarix Tetra), for all age groups for which it is indicated. Of note, the different brand names by country refer to the same medicinal product (IIV4). The primary objective was to estimate the cumulative percentage of subjects reporting AEIs and/or other AEs, using the AERC, within 7 days following vaccination with IIV4. The secondary objectives were to estimate the weekly and cumulative data by age strata (6 months–17 years; 18–65 years; > 65 years), and risk status (at risk/not at risk). Results of the interim analysis showing weekly AEs reported from week 40 to 52 overall and by country are presented here.

Methods

Study Setting and Population

This ESS study was a prospective multicenter study in Belgium, Germany, and Spain of GSK’s IIV4 during the 2018/19 influenza season. Nine healthcare professionals (HCP) (three in each country) aimed to recruit a total of 1000 subjects (aged 18 years or older in Belgium and Germany, and 6 months or older in Spain) who received IIV4. Vaccination must have been performed in routine clinical practice according to local prescribing information, with one dose for subjects previously vaccinated against influenza or aged over 9 years, and two doses (4 weeks apart) for subjects aged under 9 years and not previously vaccinated against influenza [9]. Written informed consent/assent was obtained from subjects or their parents/guardians prior to enrollment. Subjects aged 6 months or older at the time of vaccination with IIV4, who consented and who would, according to investigators, comply with the protocol, were included in the study. Children in care were excluded from the study (i.e., children under the control or protection of an agency, organization, institution, or entity by the courts, the government, or a government body, acting in accordance with powers conferred on them by law or regulation).

The study was conducted between October 1, 2018 and January 4, 2019 with recruitment planned from October 1 to December 31, 2018 for subjects requiring one dose, and from October 1 to December 1, 2018 for subjects requiring two doses. Study follow-up was approximately 8 days for subjects vaccinated with one dose and 36 days for subjects vaccinated with two doses.

Selection of Countries

A feasibility assessment of suitable countries for the conduct of this study was made and suitable research groups and sites were contacted. The study was conducted in Belgium, Germany, and Spain. Despite similar vaccine recommendations in these three countries (primarily targeting older adults and children at risk for annual influenza vaccination), sites in Spain that responded favorably were essentially pediatric sites, while Belgium and Germany have limited vaccine coverage in children. As such, Belgium and Germany only recruited subjects 18 years of age and above (with German participating sites targeting subjects aged 50 years and older). Spain targeted the enrollment of subjects between 6 months and 65 years of age at the time of the vaccination. This study was thus able to capture data on AEs in all age groups with an indication for GSK’s seasonal influenza vaccine, regardless of the target population for vaccination.

Safety Data Collection and Analysis

This study aimed to capture AEs in near real time in order to rapidly estimate the reporting rate of AEIs experienced within days of vaccination. Weekly data reviews and four interim analyses were conducted. The results of the fourth interim analysis are presented here. An AE was defined as any untoward medical occurrence, temporally associated with the use of a medicinal product (whether or not related to the product) or with a study procedure. The HCPs provided each vaccinee or their parent/guardian with a customized AERC to be completed from the day of vaccination and for the following 6 days. The AERC includes predefined categories of AEIs representing events commonly associated with IIV4 s, along with a free text field to report any other AE, and the possibility to indicate that no AE occurred in the 7-day timeframe. Subjects were asked to return the AERC to their HCP at the next scheduled visit or by mail within 2 weeks of vaccination. Practice staff then entered the information in an electronic Case Report Form (eCRF), using a code list provided to each practice to standardize data collection and analysis of AEIs. Details on the AERC and eCRF were previously published by the authors [10]. Reported AEIs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) classification [11].

Statistical Considerations

In the sample size calculations, the probability of observing at least one AE was presented according to several scenarios in which the expected number of vaccinees and true percentage of subjects experiencing an AE were tabulated. Those scenarios were previously reported in the published protocol [10]. Of note, the planned number of study subjects to be enrolled (n = 1000) was expected to enable detection of the very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1000 to < 1/100) AEIs, and/or other AEs.

Demographic data collected for all subjects, including age, gender, geographic ancestry, and risk status, are presented for the overall study population. The HCP assessed and recorded each subject as at risk/not at risk for influenza-associated morbidity and mortality according to the local recommendations. Of note, in Europe, according to ECDC [12], risk groups should include pregnant women, subjects with chronic conditions (e.g., heart or lung diseases, metabolic or renal disease, chronic liver disease, chronic neurological conditions, or immunodeficiencies), older subjects in long-term care facilities, children aged 6–59 months, and healthcare workers. The interim analysis was conducted on all vaccinated subjects who received the AERC. The number and percentage of vaccinated subjects are presented by country and center, by International Standards Organization (ISO) week) of vaccination, and by age category (6 months–17 years, 18–65 years, over 65 years). The number and percentage of subjects returning their AERC are presented by country/center and for dose 1 and dose 2. The occurrences of AEs are presented by AEI or other AE by Preferred Term (PT) by vaccination week (expected ISO weeks 40–52) using the MedDRA classification for Primary System Organ Class, overall and by country. All analyses were descriptive in nature and did not aim to allow direct comparisons. The extended Clopper–Pearson exact confidence interval (CI) for cluster data was used to compute 95% CI on all estimated percentages, accounting for clustering effect of centers [13].

Compliance with Ethics Guidelines

The study was conducted in accordance with the International Conference on Harmonisation (ICH) Guideline for Good Clinical Practice, Good Epidemiology Practice, Good Pharmacovigilance Practice, or other applicable guidelines, all applicable subject privacy requirements and the guiding principles of the Declaration of Helsinki. The study was designed and conducted in accordance with the ICH Harmonised Tripartite Guideline for clinical investigation of medicinal products in the paediatric population (ICH E11) and all other applicable ethical guidelines. GSK obtained favourable opinion/approval to conduct the study prior to a site initiating the study in that country or has documented that neither a favourable opinion nor an approval to conduct the study was needed. Written informed consent/assent was obtained from subjects or their parents/guardians prior to enrolment. The study received approval from the following ethics committees (ECs), or institutional review boards (IRBs) and regional authorities were consulted consistent with country requirements, namely Commissie Medische Ethiek UZ/KU Leuven (EC) in Belgium (approval received 24 August); Ethik-Kommission der Bayerischen (EC) in Germany (approval received 20 September), and in Spain the PEIBA (IRB and RA combined) for Andalusia (approval received 26 September) and Hospital Vall de Hebron (IRB) and Goli Gurina (RA) for Catalonia (approval received 22 October). GSK posted the study protocol on GSK’s Clinical Study Register (accessible at www.gsk-clinicalstudyregister.com, GSK Study ID 207737) and on the US National Library of Medicine website www.clinicaltrials.gov (NCT03688620).

Results

In total, 1060 vaccinated subjects were included between October 5, 2018 (ISO week 40) and December 31, 2018 (ISO week 52), of which 329 (31.0%) were from Belgium, 278 (26.2%) were from Germany, and 453 (42.7%) were from Spain (Table 1). All subjects were vaccinated with dose 1 and 139 subjects aged less than 9 years in Spain received dose 2. All subjects in the age category 6 months–17 years (n = 339, 32.0%) were from Spain, while 358 subjects (33.8%) aged 18–65 years were from all three countries and 363 subjects (34.2%) aged over 65 years were from Belgium and Germany (Fig. 1). The median age of subjects was 68 years in Belgium and Germany and 6 years in Spain (mean age overall 42.8 years). Overall 51.3% of subjects were female and 98.0% were Caucasian. Subjects assessed as being at risk for influenza-associated morbidity and mortality were distributed as follows: 204 (62.0%) in Belgium, 133 (47.8%) in Germany, and 223 (49.2%) in Spain (Table 2). For those subjects receiving two doses, median age was 3 years, 42.2% were female, 99.3% were Caucasian, and 34.5% were assessed as at risk for influenza-associated morbidity and mortality.

Table 1.

Number of vaccinated subjects enrolled by center and by age group

Country	Total vaccinated subjects enrolled, N = 1060
	Center	N	%a	Age group	N	%a
Belgium	237303	129	12.2	6 months–17 years	0	0
	237304	36	3.4	18–65 years	133	12.5
	237305	164	15.5	> 65 years	196	18.5
	All	329	31.0	All	329	31.0
Germany	237278	135	12.7	6 months–17 years	0	0
	237279	93	8.8	18–65 years	111	10.5
	237280	50	4.7	> 65 years	167	15.8
	All	278	26.2	All	278	26.2
Spain	236682	250	23.6	6 months–17 years	339	32.0
	236684	153	14.4	18–65 years	114	10.8
	237680	50	4.7	> 65 years	0	0
	All	453	42.7	All	453	42.7

N total number of subjects, n number and % (percentage) of subjects in a given center or age group and country

^aDue to the rounding of the percentages to 1 decimal, the total may not equal 100%

Fig. 1.

Number of subjects vaccinated during the study using dose 1 and dose 2, by age category (pediatric, 6 months–17 years; adult, 18–65 years; older adult, > 65 years), country, and per ISO week (40–52). Two colors are used for Spain, where some pediatric subjects received two vaccination doses. ISO wk International Standards Organization week, mo month, N total number of subjects in category, y year

Table 2.

Summary of demographic characteristics and risk status for influenza-associated morbidity and mortality (ISO weeks 40–52, dose 1)

	Belgium N = 329		Germany N = 278		Spain N = 453		Overall N = 1060
	Value or n	%	Value or n	%	Value or n	%	Value or n	%
Age (year) at dose 1 vaccination
Median	68.0		68.5		6.0		48.0
Maximum	91		100		64		100
Minimum age (month/year) at dose 1 vaccination	23 years		18 years		6 months		6 months
Age category at dose 1 vaccination
6 months–17 years	0	0.0	0	0.0	339	74.8	339	32.0
18–65 years	133	40.4	111	39.9	114	25.2	358	33.8
> 65 years	196	59.6	167	60.1	0	0.0	363	34.2
Gender
Female	147	44.7	166	59.7	231	51.0	544	51.3
Male	182	55.3	112	40.3	222	49.0	516	48.7
Geographic ancestry
Black or African American	0	0.0	2	0.7	1	0.2	3	0.3
Asian—Central/South Asian	1	0.3	1	0.4	1	0.2	3	0.3
Asian—East Asian	4	1.2	1	0.4	0	0.0	5	0.5
Asian—South East Asian	2	0.6	0	0.0	0	0.0	2	0.2
White—Arabic/North African	1	0.3	0	0.0	3	0.7	4	0.4
White—Caucasian/European	321	97.6	274	98.6	444	98.0	1039	98.0
Other	0	0.0	0	0.0	4	0.9	4	0.4
Risk status: influenza-associated morbidity and mortalitya
At risk	204	62.0	133	47.8	223	49.2	560	52.8
Not at risk	125	38.0	145	52.2	230	50.8	500	47.2

ISO International Standards Organization, N number of subjects vaccinated, n number and % (percentage) of vaccinated subjects in a given category

^aAssessed by the HCP based on his/her judgment and experience

The majority of subjects aged 6 months–17 years received dose 1 in ISO weeks 42–45 in Spain. Most adults (18–65 years) in Belgium and Germany were vaccinated earlier (in ISO week 42 for Belgium and ISO weeks 40–42 for Germany) while those in Spain were mostly vaccinated later (ISO weeks 45–46). Among the older adults (> 65 years), most in Germany were vaccinated early (ISO weeks 40–42) while those in Belgium were typically vaccinated later (ISO weeks 43–46) (Fig. 1).

Following each vaccination, all subjects received an AERC to complete and return. Overall, by January 14, 2019, 98.2% of AERCs were returned (94.8% in Belgium, 99.6% in Germany, and 99.8% in Spain) for dose 1. For dose 2 in Spain, 100% of AERCs were returned (Table 3).

Table 3.

Number (%) of subjects who returned the AERC by center and country

Country	Center	Dose 1			Dose 2
		N	AERC returned		N	AERC returned
			n	%		n	%
Belgium	237303	129	112	86.8	–	–	–
	237304	36	36	100	–	–	–
	237305	164	164	100	–	–	–
	All	329	312	94.8	–	–	–
Germany	237278	135	134	99.3	–	–	–
	237279	93	93	100	–	–	–
	237280	50	50	100	–	–	–
	All	278	277	99.6	–	–	–
Spain	236682	250	250	100	116	116	100
	236684	153	152	99.3	4	4	100
	237680	50	50	100	19	19	100
	All	453	452	99.8	139	139	100
Overall	All	1060	1041	98.2	139	139	100

AERC adverse event reporting card, N number of subjects vaccinated who received the AERC, n number and % (percentage) of subjects vaccinated who returned the AERC as specified

The percentage of subjects reporting AEIs and other AEs (classed according to MedDRA Primary System Organ Class [PSOC] and Preferred Term [PT]) is presented for all countries following dose 1 (Table 4) and dose 2 (Table 5).

Table 4.

Number (%) of subjects reporting AEIs and other AEs within 7 days post-dose 1 (i.e., vaccination day and following 6 days) using AERC for all countries (N = 1060)

MedDRA primary system organ class (CODE)	N = 1060
Preferred term (code)	n	%
Any	454	42.8
Any general disorders and administration site conditions (10018065)	301	28.4
Injection site pain (10022086)*	185	17.5
Injection site swelling (10053425)*	80	7.5
Fatigue (10016256)*	69	6.5
Injection site erythema (10022061)*	56	5.3
Pyrexia (10037660)*	33	3.1
Chills (10008531)*	25	2.4
Injection site pruritus (10022093)	4	0.4
Face edema (10016029)*	2	0.2
Influenza-like illness (10022004); mucous membrane disorder (10028133); peripheral swelling (10048959)	2 each	0.2 each
Discomfort (10013082); feeling cold (10016326); feeling hot (10016334); injection site hematoma (10022066); injection site reaction (10022095); injection site warmth (10022112); malaise (10025482)	1 each	0.1 each
Any respiratory, thoracic, and mediastinal disorders (10038738)	184	17.4
Rhinorrhea (10039101)*	91	8.6
Cough (10011224)*	71	6.7
Nasal congestion (10028735)*	56	5.3
Oropharyngeal pain (10068319)*	49	4.6
Dysphonia (10013952)*	23	2.2
Epistaxis (10015090)*	9	0.8
Wheezing (10047924)*	6	0.6
Dyspnea (10013968); sneezing (10041232)	3 each	0.3 each
Dry throat (10013789); increased upper airway secretion (10062717); pharyngeal inflammation (10065716); throat clearing (10080125)	1 each	0.1 each
Any musculoskeletal and connective tissue disorders (10028395)	95	9.0
Myalgia (10028411)*	71	6.7
Arthropathy (10003285)*	32	3.0
Pain in extremity (10033425)	3	0.3
Rheumatic disorder (10072736)	2	0.2
Limb discomfort (10061224); muscle spasms (10028334); musculoskeletal pain (10028391); synovial cyst (10042858)	1 each	0.1 each
Any nervous system disorders (10029205)	85	8.0
Headache (10019211)*	78	7.4
Dizziness (10013573)	4	0.4
Aphonia (10002953); poor quality sleep (10062519); somnolence (10041349); tremor (10044565)	1 each	0.1 each
Febrile convulsion (10016284)*	0	0.0
Any gastrointestinal disorders (10017947)	67	6.3
Diarrhea (10012735)*	32	3.0
Nausea (10028813)*	32	3.0
Vomiting (10047700)*	19	1.8
Abdominal pain (10000081)	3	0.3
Gingival bleeding (10018276); lip swelling (10024570); stomatitis (10042128); tongue discomfort (10077855)	1 each	0.1 each
Any infections and infestations (10021881)	66	6.2
Conjunctivitis (10010741)*	36	3.4
Rhinitis (10039083)*	30	2.8
Nasopharyngitis (10028810)	3	0.3
Bronchitis (10006451); ear infection (10014011); herpes simplex (10019948); hordeolum (10020377); laryngitis (10023874); oral herpes (10067152); upper respiratory tract infection (10046306)	1 each	0.1 each
Any metabolism and nutrition disorders (10027433)	32	3.0
Decreased appetite (10061428)*	32	3.0
Any psychiatric disorders (10037175)	19	1.8
Irritability (10022998)*	18	1.7
Insomnia (10022437); mood swings (10027951); sleep disorder (10040984)	1 each	0.1 each
Any skin and subcutaneous tissue disorders (10040785)	17	1.6
Pruritus (10037087)	8	0.8
Rash (10037844)*	7	0.7
Erythema (10015150)	2	0.2
Hyperhidrosis (10020642); pruritus generalized (10052576)	1 each	0.1 each
Rash generalized (10037858)*	0	0.0
Any ear and labyrinth disorders (10013993)	7	0.7
Ear pain (10014020); vertigo (10047340)	2 each	0.2 each
Ear hemorrhage (10014009); ear pruritus (10052138); tinnitus (10043882)	1 each	0.1 each
Any immune system disorders (10021428)	6	0.6
Hypersensitivity (10020751)*	6	0.6
Anaphylactic reaction (10002198)*	0	0.0
Any investigations (10022891)	4	0.4
Heart rate increased (10019303)	4	0.4
Any eye disorders (10015919)	3	0.3
Eye pruritus (10052140); lacrimation increased (10023644); swelling of eyelid (10042690)	1 each	0.1 each
Any injury, poisoning, and procedural complications (10022117)	1	0.1
Muscle strain (10050031)	1	0.1
Any cardiac disorders (10007541)	1	0.1
Tachycardia (10043071)	1	0.1

AE adverse event, AEI adverse event of interest, AERC adverse event reporting card, MedDRA Medical Dictionary for Regulatory Activities [11], N total number of subjects, n number of subjects in category

*AEI

Table 5.

Number (%) of subjects reporting AEIs and other AEs within 7 days post-dose 2 (i.e., vaccination day and following 6 days) using AERC in Spain

MedDRA primary system organ class (CODE)	N = 139
Preferred term (code)	n	%
Any	34	24.5
Any respiratory, thoracic, and mediastinal disorders (10038738)	21	15.1
Cough (10011224)*	12	8.6
Rhinorrhea (10039101)*	9	6.5
Nasal congestion (10028735)*	7	5.0
Dysphonia (10013952)*	3	2.2
Wheezing (10047924)*	2	1.4
Epistaxis (10015090)*	1	0.7
Sneezing (10041232)	1	0.7
Oropharyngeal pain (10068319)*	0	0.0
Any general disorders and administration site conditions (10018065)	11	7.9
Injection site pain (10022086)*	7	5.0
Pyrexia (10037660)*	6	4.3
Chills (10008531)*	0	0.0
Face edema (10016029)*	0	0.0
Fatigue (10016256)*	0	0.0
Injection site erythema (10022061)*	0	0.0
Injection site swelling (10053425)*	0	0.0
Any infections and infestations (10021881)	5	3.6
Conjunctivitis (10010741)*	4	2.9
Rhinitis (10039083)*	1	0.7
Any gastrointestinal disorders (10017947)	4	2.9
Diarrhea (10012735)*	2	1.4
Vomiting (10047700)*	1	0.7
Abdominal pain (10000081)	1	0.7
Nausea (10028813)*	0	0.0
Any metabolism and nutrition disorders (10027433)	4	2.9
Decreased appetite (10061428)*	4	2.9
Any psychiatric disorders (10037175)	4	2.9
Irritability (10022998)*	4	2.9
Any eye disorders (10015919)	2	1.4
Eye pruritus (10052140)	2	1.4
Any musculoskeletal and connective tissue disorders (10028395)	1	0.7
Myalgia (10028411)*	1	0.7
Arthropathy (10003285)*	0	0.0
Any skin and subcutaneous tissue disorders (10040785)	1	0.7
Rash (10037844)*	1	0.7
Rash generalized (10037858)*	0	0.0
Any immune system disorders (10021428)	0	0.0
Anaphylactic reaction (10002198)*	0	0.0
Hypersensitivity (10020751)*	0	0.0
Any nervous system disorders (10029205)	0	0.0
Febrile convulsion (10016284)*	0	0.0
Headache (10019211)*	0	0.0

AE adverse event, AEI adverse event of interest, AERC adverse event reporting card, MedDRA Medical Dictionary for Regulatory Activities [11], N total number of subjects, n number of subjects in category

*AEI

Overall, among the 1060 vaccinated subjects, 454 subjects (42.8%) reported at least one AE after dose 1. The most frequently reported AEs were on the predefined list of AEIs, i.e., injection site pain (17.5%), rhinorrhea (8.6%), injection site swelling (7.5%), headache (7.4%), myalgia (6.7%), cough (6.7%), fatigue (6.5%), injection site erythema (5.3%), nasal congestion (5.3%), and oropharyngeal pain (4.6%). Some predefined AEIs were not reported, i.e., there were no cases of anaphylaxis, generalized rash, febrile convulsion, Bell’s palsy, or Guillain–Barré syndrome. Other AEIs were less frequent, reported in 0.2–3.4% of subjects. Regarding AEs not on the predefined list, the most frequently reported was pruritus (0.8%), while other AEs were reported for 0.1–0.4% of subjects. The most frequently reported MedDRA PSOC of AEs were general disorders and administration site conditions (n = 301, 28.4%), followed by respiratory, thoracic ,and mediastinal disorders (n = 184, 17.4%), musculoskeletal and connective tissue disorders (n = 95, 9.0%), nervous system disorders (including headache) (n = 85, 8.0%), gastrointestinal disorders (n = 67, 6.3%) ,and infections and infestations (n = 66, 6.2%). The remaining classes of AEs were reported by 3% or fewer subjects (Table 4).

The overall frequency of AEs reported after dose 1 was similar (i.e., 41.9% in Belgium, 36.7% in Germany, and 47.2% in Spain), and the ranking and frequencies of the most common classes of AEs were mostly of similar magnitude: general disorders reported by 26.7–30.0% of subjects, respiratory disorders by 11.5–23.0%, musculoskeletal disorders by 8.3–10.3%, nervous system disorders (including headache) by 7.9–8.2%, gastrointestinal disorders by 5.0–6.8%, and infections by 4.6–7.9%. In Spain, metabolism disorders (i.e., decreased appetite) were also reported by 5.3% of subjects.

In Spain, among the 139 pediatric subjects who received dose 2, 34 subjects reported at least one AE. The most frequently reported AEs were on the predefined list of AEIs and were classed as respiratory, thoracic, and mediastinal disorders (n = 21, 15.1%) of which cough (8.6%), rhinorrhea (6.5%), and nasal congestion (5.0%) were most frequent. The next most frequently reported AEIs were general disorders and administration site conditions (n = 11, 7.9%) of which injection site pain (5.0%) and pyrexia (4.3%) were most frequent. Other AEIs were reported by 0.7–2.9% of subjects. There were no reports of the following AEIs: headache, febrile convulsion, anaphylaxis, hypersensitivity, generalized rash, arthropathy, nausea, injection site swelling or erythema, fatigue, chills, face edema, oropharyngeal pain, Bell’s palsy, or Guillain–Barré syndrome. AEs not on the predefined list were reported by 0.7–1.4% of subjects (i.e., one case each of sneezing and abdominal pain and two cases of eye pruritus) (Table 5).

In addition, during the study period, according to HCPs judgement, no serious AEs deemed to be related to GSK’s IIV4 were reported within 7 days post vaccination.

In the electronic supplementary material, the percentage of subjects with AEs by ISO week following dose 1 and dose 2 is presented overall and by country. See Tables S1–S5 in the electronic supplementary material for details.

Discussion

At the interim analysis in this study, 100% of AERCs were returned for two out of three centers in each country, while the return rate was 86.8–99.3% for the remaining centers for dose 1. For dose 2, 100% of AERCs were returned. Following dose 1, interim results showed that 454 subjects reported at least one AE within 7 days of vaccination among the 1060 subjects. The most frequently reported were on the predefined list of AEIs, i.e., local injection site reactions and general symptoms (headache, fatigue), respiratory symptoms (rhinorrhea, cough, nasal congestion, oropharyngeal pain), and myalgia. These AEIs were expected events commonly observed after vaccination with an IIV4 [14].

Ongoing reviews of raw data during the study period and the interim analyses did not detect any safety signals that could affect public health or could alter the benefit–risk profile of GSK’s IIV4.

The methodology used for data collection and analysis (i.e., customized AERC completed by subjects and coded into eCRFs by practice staff using a MedDRA-based coding list) also appears to have been successful and a promising approach, with a return rate for AERCs that was in the same range or above the return rate observed in active surveillance. There are two possible explanations for the high return rate: firstly, feedback following similar studies in the UK has revealed a growing interest from patients to participate actively in their health follow-up; and secondly, the study included a planned visit following vaccination, to encourage continued subject participation (see protocol [10]). In Italy, active surveillance 7 days after influenza vaccination involving a follow-up telephone interview or web-based platform resulted in a 97% response rate overall [15]. In the Netherlands, a web-based questionnaire had response rates of 90.7% at day 5, 84.5% at day 15, and 78.4% at day 30 after influenza vaccination [16].

This ESS of GSK’s IIV4 covered all age groups for which the vaccine is indicated. This was achieved through a combination of data from three European countries: Spain, where pediatric subjects were enrolled (from 6 months of age), as well as Germany and Belgium, all of which use IIV4 in adults and older adults. The distribution of subjects across countries and across age categories was generally balanced. The target number of patients was reached in the 3-month recruitment period, with sufficient data collected in a relatively short period of time, as the majority of subjects were vaccinated and enrolled within a 4-week timeframe. Data were also reviewed on an ongoing basis in near real time owing to the electronic application and data collection methods used.

A recent review summarizes several other initiatives conducted so far to address the EMA requirement for enhanced safety surveillance of seasonal influenza vaccines, and illustrates a diverse range of approaches used in Europe (e.g., patient diaries, patient records, interviews) with their challenges. Several studies reported difficulties with the recruitment of pediatric participants or with achieving high response rates [17].

A key strength of this study was the inclusion of a large and diverse group of subjects of all ages for which IIV4 is indicated, and from participating countries with different vaccination practices. Nevertheless, the relatively low number of subjects included did not allow investigation of potential disparities, across age groups notably, which deserves further attention in the future. The study procedures and prospective data collection proved to be successful, given the high return rate of AERCs. The use of an electronic application to collect standardized data (eCRFs using the coded AEI list) simplified data extraction, cleaning, and analysis to facilitate near-real-time assessment of the safety data, and will allow for future comparisons. The main limitations of this observational study were the absence of formal baseline rates for comparison (although final results can be discussed in light of the expected AE rates from clinical trials reported in the smPC), the limited timeframe for AE detection which is not adequate to fully capture AEs with a longer risk period, and that the enrollment period was dependent on the timing of vaccination campaigns in participating countries. Enrollment, thus, could not begin before mid to end October at most participating centers. This was, however, mitigated by a fast recruitment period, condensed into approximately 4 weeks. Given the small number of participating centers, the participants (mainly white-Caucasian) may not be representative of all inhabitants in these countries. Furthermore, the sample size was not large enough to allow for the assessment of rare AEs; however, on the basis of the EMA guidance, this was not an objective of the study.

Conclusion

Importantly, this interim analysis did not show any safety signals for GSK’s IIV4 in the 2018/19 influenza season that could impact public health or the known safety profile of the vaccine. Further analyses will describe the reported AEs in more detail and confirm the current safety findings. This multi-country study and the proposed ESS methodology were successful in rapidly providing safety data from subjects of all ages for whom IIV4 is indicated. It offered a suitable approach for the continuous monitoring of seasonal influenza vaccines, overcoming the underreporting frequently observed with passive initiatives.

Electronic supplementary material

Below is the link to the electronic supplementary material.